Combination of PD-991 and letrozole improves survival in patients with HER2- breast cancer

Pfizer Inc. today announced randomized Phase 2 data that showed PD-0332991 (PD-991) in combination with letrozole significantly extended progression free survival (PFS) compared with letrozole alone in post-menopausal patients with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer.

Read more...
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

8 Ways to Trick Yourself Thin

8 Ways to Trick Yourself Thin An article from By Chris Freytag The formula for weight loss may be simple-take in fewer calories ...